FTS3‐03‐02: Progress on Alzheimer’s Research Funding: How It has Happened

not available. FTS3-02-04 NEW FRONTIERS IN STROKE AND DEMENTIA TREATMENTAND PREVENTION Vladimir Hachinski, Western University, London, ON, Canada. Contact e-mail: Vladimir.Hachinski@lhsc.on.ca Background: Stroke and dementia pose the greatest threat to the mature and aging brain. Considerable advances have been made in the diagnosis, treatment and prevention of stroke. Although knowledge about dementia has grown apace, no comparable progress has been made in the treatment and prevention of dementia. Methods: Cerebrovascular and Alzheimer pathologies not only often coexist, but interact in the brain. Moreover, stroke and dementia share the same treatable risk factors. Some risk factors additionally may accelerate neurodegenerative processes, such as hypertension enhancing amyloid deposition and hyperhomocysteinemia facilitating tau protein aggregation. Results: Recently a decrease in dementia incidence concomitant with a successful stroke strategy has been shown at a whole population level. The Alzheimer Association and 21 other international, regional and national organizations have committed to a stroke and preventable dementia proclamation calling for their joint prevention. Additionally, potentially treatable interactions between Alzheimer and cerebrovascular pathologies are drawing growing attention. Conclusions: New frontiers are being explored both in common strategies and in a diversity of tactics. TUESDAY, JULY 26, 2016 FOCUSED TOPIC SESSIONS FTS3-03 THE U.S. NATIONAL ALZHEIMER’S PLAN WHERE ARE WE, HOW DID WE GET THERE, ANDWHERE ARE WE GOING? FTS3-03-01 THEU.S. NATIONALALZHEIMER’S PLAN: FIVE YEARS LATER Ronald C. Petersen, Mayo Clinic, Rochester, MN, USA; U.S. Advisory Council on Alzheimer’s Research, Care, and Services, Washington, DC, USA. Contact e-mail: peter8@mayo.edu Background: The creation of the U.S. National Alzheimer’s Plan forged new territory for the Department of Health and Human Services. It was meant to catalyze the country into action in the fight against Alzheimer’s disease. With the fifth iteration of the plan recently released, what has been accomplished? What progress has been made? Dr. Petersen, who has chaired the advisory group on the National Plan since its inception, will answer those questions in this overview presentation that looks back over the last five years. Methods:Not applicable. Results:Not applicable. Conclusions:Not applicable. FTS3-03-02 PROGRESS ON ALZHEIMER’S RESEARCH FUNDING: HOW IT HAS HAPPENED Robert Egge, Alzheimer’s Association, Washington, DC, USA. Contact e-mail: regge@alz.org Background:The U.S. National Alzheimer’s Plan and the significant increases in research funding as a result of the Plan have not happened in a vacuum. They resulted from organized, focused, andwidespread efforts involving amultiyear policy strategy backed by a rapid mobilization of grassroots advocates across the United States. Mr. Egge will walk through how it was all accomplished – from the original legislation calling for a National Plan to the $350 million increase in funding for fiscal year 2016. Methods: Not applicable. Results:Not applicable. Conclusions:Not applicable. FTS3-03-03 RESEARCH ON CARE AND SUPPORT INTERVENTIONS: WHERE ARE WE AND WHERE DOWE NEED TO GO? Laura N. Gitlin, Johns Hopkins Center for Innovative Care in Aging, Baltimore, MD, USA. Contact e-mail: lgitlin1@jhu.edu Background:To date, most policy progress since the release of the first U.S. National Alzheimer’s Plan has centered on biomedical research. But the Plan also seeks to improve care and support both for those with the disease and their unpaid family and friend caregivers. Dr. Gitlin will discuss the current state of knowledge on non-pharmacological care and social support interventions, the research needed to fill the gaps, and what should happen next under the U.S. National Plan.Methods:Not applicable. Results:Not applicable. Conclusions:Not applicable. FTS3-03-04 IMPLEMENTATION OFALZHEIMER’S DISEASE RESEARCH PLANS: STEPWISE PROGRESS TOWARD THE MILESTONES Richard J. Hodes, National Institute on Aging, Bethesda, MD, USA. Contact e-mail: hodesr@31.nia.nih.gov Background:The National Institutes of Health (NIH) has recently issued funding announcements on Alzheimer’s and related dementias research. Dr. Hodes will outline these opportunities, how they are connected to specific research milestones, and the response to date. In addition, he will discuss the National Institute on Aging’s Alzheimer’s disease research process: how the ongoing funding shapes future planning efforts and how these efforts integrate with research planning across the NIH. Methods: Not applicable. Results:Not applicable. Conclusions:Not applicable. TUESDAY, JULY 26, 2016 PLENARY SESSIONS PL-03 PL-03-01 INGE GRUNDKE-IQBAL LECTURE FOR ALZHEIMER’S RESEARCH: EXOSOMES AND MICROGLIA IN TAU PROPAGATION Tsuneya Ikezu, Boston University School of Medicine, Boston, MA, USA. Contact e-mail: tikezu@bu.edu Abstract not available.not available. PL-03-02 A MOVING TARGET? DEMENTIA IN CHANGING OLDER POPULATIONS Carol Brayne, University of Cambridge, Cambridge, United Kingdom. Contact e-mail: cb105@medschl.cam.ac.uk Background: The dementia syndrome is an umbrella term which captures not only the dementias associated with familial monogenic risk but also the range of dementias caused by noxious exposures such as head injuries, alcohol and HIV, as well as vascular insults. These dementias are those more often seen in younger age groups. However most dementia in countries with long life expectancies are those experienced in later life, well after traditional retirement ages. Podium Presentations: Tuesday, July 26, 2016 P278